India's largest drugmaker by revenue, Sun Pharmaceutical Industries, delivered impressive quarterly results that exceeded market expectations. According to the latest reports from Outlook Business, the company's consolidated net profit stood at ₹2,714.03 crore for the quarter ended March 31, 2026, representing a significant increase from ₹2,149.88 crore in the corresponding quarter of the previous year. This performance was above analysts' average estimate of ₹2,712 billion, demonstrating the company's strong operational execution during the quarter. The company also reported total revenue from operations of ₹14,611.79 crore compared to ₹12,958.84 crore in the year-ago period, with total expenses rising to ₹11,518.95 crore from ₹9,955.68 crore in the same period. The company's board has proposed a final dividend of ₹5 per share for FY26, in addition to the interim dividend of ₹11 per share, taking the total dividend for FY26 to ₹16 per share.
The company's strategic focus on higher-margin specialty medicines proved highly effective in driving quarterly growth. As reported by Outlook Business, Sun Pharma has been expanding into specialty medicines with a sharper focus on areas such as dermatology, oncology and obesity to offset declining US sales. The specialty segment accounted for 22.2% of total sales, with revenue rising 20.1% to $354 million during the quarter. This growth was particularly strong in India, where formulation sales were at ₹4,835.9 crore, registering 14.8% growth and accounting for 33.2% of total consolidated sales. The company has now renamed its specialty business as the "innovative medicines" business, reflecting its increasing focus on differentiated and specialty-led therapies across global markets. For the full year FY26, global innovative medicines sales were $1,420 million, up 16.8%, demonstrating sustained momentum in this high-margin segment.
Overall revenue performance was equally impressive, with the company reporting nearly 13.61% growth to ₹14,611.79 crore, which also surpassed analysts' estimates of ₹14,526 crore. According to Outlook Business, this revenue growth was driven by strong performance in specialty drugs and formulation sales in India. The Mumbai-based pharmaceutical giant's ability to offset weakness in US sales through specialty drug expansion demonstrates the effectiveness of its diversification strategy. Research and development investment during the quarter stood at ₹975.7 crore, equivalent to 6.7% of sales, reflecting the company's continued commitment to innovation and product development.
Despite the strong overall performance, Sun Pharma faced some challenges in its key US market during the quarter. As reported by Outlook Business, US formulations sales were $459 million, lower by 1.1% in the quarter under review, highlighting ongoing challenges in the American pharmaceutical market. However, the company's US innovative medicines business has surpassed $1 billion in revenues, while ex-US innovative medicines continue to demonstrate strong growth momentum. US sales accounted for approximately 28.8% of total consolidated sales in Q4, with the company's strategic pivot toward specialty medicines helping mitigate US market headwinds. For the full year FY26, US formulations sales were $1,904 million, showing resilience despite quarterly challenges.
For the full financial year ended March 2026, Sun Pharma demonstrated consistent growth across key metrics. According to Outlook Business, net profit rose 5.04% to ₹11,479.42 crore compared to ₹10,929.04 crore in the previous year, while total revenue from operations stood at ₹58,462.04 crore compared to ₹52,578.44 crore in FY25. The company's operating profit margin improved to 27.16% from 29.35% in the previous year, while PBDT increased 14% to ₹4,326.81 crore from ₹3,936.42 crore. Managing Director Kirti Ganorkar highlighted that "Our full-year performance reflects several significant achievements. Sun's 0.3 percentage point gain in the India market is our highest gain since the Ranbaxy acquisition," as reported by Outlook Business. He further noted that the recently announced Organon acquisition is expected to further accelerate Sun Pharma's transformation into a leading global pharmaceutical company.
